Administration of epigallocatechin-3-gallate for microdermabrasion

Abstract


Rationale of the study As previously demonstrated, epigallocatechin-3-gallate (EGCG) accelerates the formation of the collagenous matrix and at the same time prevents any extraordinary collagen synthesis in the course of wound healing. In addition, EGCG is one of the most potent antioxidants and can inhibit cyclooxygenase-2, which in general lays the basis for studying the possibility to use it as an anti-inflammatory drug after dermabrasion procedures as well as to prevent pathologic cicatrization. Materials and methods. Forty women were divided into two groups (21 patients in the group treated with Egallohit, 10% EGCG, and 19 patients treated with Pantoderm Cream, 5% dexpanthenol). The drugs were applied twice a day for 50 days. Dermabrasion was performed on Days 1, 12 and 24. The patients were examined at Days 3, 15, 27, 36 and 60 of the treatment. Each of them filled in a questionnaire about the facial skin pain and itching. The facial skin humidity, fatness and pigmentation as well as number and depth of wrinkles were also measured. The total skin photodegradation index (by a blinded appraiser) was also assessed at the first and last visit. Results. No statistically significant differences in the number and depth of wrinkles, intensity and duration of facial skin pain and itching as well as skin photodegradation index between the groups both prior to and after the treatment were revealed. Conclusions. EGCG (10% Egallohit Gel) is as efficient for skin protection after microdermabrasion procedures as conventional drugs (5% cream with dexpanthenol).

About the authors

Z R KHISMATULLINA

References

  1. Kapoor M., Howard R., Hall I., Appleton I. Effects of epicatechin gallate on wound healing and scar formation in a full thickness incisional wound healing model in rats // Am. J. Pathol. 2004. Vol. 165. P. 299-307.
  2. Zhang Q., Kelly A.P., Wang L., French S.W., Tang X., Duong H.S., Messadi D.V., Le A. D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways // J. Invest. Dermatol. 2006. Vol. 126, № 12. P. 2607-2613.
  3. Pajonk F., Riedisser A., Henke M., McBride W. H., Fiebich B. The effects of tea extracts on proinflammatory signaling // BMC Med. 2006. Vol. 4. P. 28.
  4. Tahara S., Baba N., Matsuo M., Kaneko T. Protective effect of epigallocatechin gallate and esculetin on oxidative DNA damage induced by psoralen plus ultraviolet-A therapy // Biosci. Biotechnol. Biochem. 2005. Vol. 69, № 3. P. 620-622.
  5. Yamamoto T., Staples J., Wataha J., Lewis J., Lockwood P., Schoenlein P., Rao S., Osaki T., Dickinson D., Kamatani T., Schuster G., Hsu S. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride // Anticancer Res. 2004. Vol. 24, № 5A. P. 3065-3073.
  6. Pisters K. M. W., Newman R. A., Coldman B., Shin D. M., Khuri F.R., Hong W. K., Glisson B. S., Lee J. S. Phase I trial of oral green tea extract in adult patients with solid tumors // J. Clin. Oncol. 2001. Vol. 19, № 6. P. 1830-1838.
  7. Tatti S, Swinehart J. M., Thielert C., Tawfik H., Mescheder A., Beutner K. R. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial // Obstet Gynecol. 2008; 111(6): 1371-1379.
  8. Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging // Arch Dermatol. 2005 Oct;141(10):1247-1252.
  9. Spencer JM, Kurtz ES. Approaches to document the efficacy and safety of microdermabrasion procedure // Dermatol Surg. 2006 Nov;32(11):1353-1357

Statistics

Views

Abstract - 541

PDF (Russian) - 267

PlumX

Article Metrics

Metrics Loading ...

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2010 KHISMATULLINA Z.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies